WOE of Anti-CD20 Therapies

This will be a non-interventional, primary data collection study in patients with MS treated with an established anti-CD20 treatment regimen (OCR or OMB) in the United States. Patients who satisfy the inclusion criteria and consent to participate in the study will be surveyed at four timepoints at the beginning and the end of OCR or OMB treatment cycles according to the following assessment schedule: * Assessment 1. 0-10 days before 1st dose post-enrollment (index dose) * Assessment 2: 5-14 days after index dose * Assessment 3: 0-10 days before 2nd dose post-enrollment (follow-up dose) * Assessment 4: 5-14 days after follow-up dose dose